Investment Rating - The report maintains a "Buy" rating for several companies including Tian Shi Li, Xin Da Biology, and WuXi AppTec, with a focus on the innovative drug industry and high-end medical devices [3][25]. Core Insights - The small nucleic acid drug sector is experiencing significant advancements, marking the dawn of a new wave of innovative drugs. The industry is entering a golden development period driven by technological breakthroughs and commercial validation, with a recommendation to focus on leading innovative drug companies and those benefiting from the overall industry upturn [1][20][24]. Summary by Sections Market Review - The A-share pharmaceutical and biotechnology index fell by 4.32%, underperforming the CSI 300 index by 0.54 percentage points, while outperforming the ChiNext index by 1.92 percentage points, ranking 30th among 31 sub-industries. The H-share Hang Seng Healthcare Index dropped by 7.5%, underperforming the Hang Seng Index by 2.41 percentage points [1][15][9]. R&D Progress - Recent IND applications have been initiated for Heng Rui Medicine's HRS-1358 and HRS-3738, and clinical applications for SHR-9539 and JS207 have also been newly undertaken. Additionally, Zheng Da Tian Qing's TQB2934 is in Phase I clinical trials, while Gan Li Pharmaceutical's Bo Fan Gu Lu Tai is in Phase III [1][28]. Key Company Recommendations - The report highlights key companies to watch, including Heng Rui Medicine (A+H), Xin Da Biology (H), WuXi AppTec (A+H), Qian Yan Biology, Chengdu Xian Dao, and Jian Kai Technology, focusing on those with leading technology platforms and differentiated pipelines [1][25][24]. Investment Strategy - The report emphasizes the importance of clinical value in the pharmaceutical sector, suggesting that investments should focus on innovative drug chains and medical devices that meet clinical needs. The strategy is based on a three-stage clinical value framework [2][24]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Tian Shi Li projected at 0.64 CNY for 2024, Xin Da Biology at -0.06 CNY, and WuXi AppTec at 3.27 CNY for 2024, indicating a positive outlook for several firms [3].

Core Viewpoint - Heng Rui Medicine (1276.HK) experienced a significant stock price increase, rising approximately 7% to HKD 69.6, with a total market capitalization of HKD 461.9 billion, following the announcement of multiple drug clinical trial approvals by the National Medical Products Administration [1] Group 1: Drug Approvals - The company and its subsidiaries received approval for clinical trials for several drugs, including SHR-9839, SHR-A2009, SHR-1826, HRS-4642 injection, Adalimumab injection, Trastuzumab, SHR-A2102, and HRS-7058 capsules and tablets [1] - The approval of nine drugs (excluding SHR-1139) in a single announcement highlights the company's strong research and development efficiency and a rich product pipeline, which are core components of its long-term competitiveness [1]

Core Viewpoint - Heng Rui Pharmaceutical (1276.HK) experienced a significant stock price increase, rising approximately 7% to a current price of 69.6 HKD, with a total market capitalization of 461.9 billion HKD following the announcement of multiple drug clinical trial approvals by the National Medical Products Administration [1] Group 1: Drug Approvals - The company and its subsidiaries recently received approval for clinical trials for several drugs, including SHR-9839 (sc) and SHR-A2009, among others [1] - A total of nine drugs were approved for clinical trials, demonstrating the company's strong research and development efficiency and a rich product pipeline [1] Group 2: Market Implications - The approval of multiple drugs is seen as a testament to the company's long-term competitive advantage in the pharmaceutical industry [1]

| | | 港股通创新药ETF (520880) 标的指数 | | | --- | --- | --- | --- | | | | 前十成份股权重高达71.51%，龙头优势显著 | | | 代码 | 简称 | 权重(%) | 总市值(亿港元) | | 6160.HK | 三济神州 | 10.74 | 3,022 | | 1177.HK | 中国生物制药 | 9.76 | 1,326 | | 1801.HK | 信达 参物 | 9.68 | 1,491 | | 9926.HK | 康方生物 | 8.53 | 1,045 | | 1093.HK | 有分量团 | 8.43 | 881 | | 1530.HK | 三生制药 | 8.34 | 749 | | 3692.HK | 翰森制药 | 6.04 | 2,158 | | 6990 HK | 科伦博泰生物-B | 4.16 | 1,045 | | 9688.HK | 电間居然 | 3.18 | ટટક | | 6855.HK | 亚盛医药-B | 2.65 | 248 | | 100 40 -- 10 -- 1 -- 1 -- 1 -- | 合计 | 71.51 ...

Core Viewpoint - Heng Rui Pharmaceutical (01276.HK) has seen a stock price increase of over 5%, currently trading at 69.3 HKD with a transaction volume of 141 million HKD [1] Group 1 - The stock price of Heng Rui Pharmaceutical rose by 5.08% [1] - The current trading price is 69.3 HKD [1] - The total transaction volume reached 1.41 billion HKD [1]

Core Viewpoint - Heng Rui Medicine (600276) (01276) saw a rise of over 5%, currently up 5.08% at HKD 69.3, with a trading volume of HKD 141 million [1] Group 1: Company Developments - On November 21, Heng Rui Medicine announced that it, along with its subsidiaries, received approval from the National Medical Products Administration for multiple clinical trial applications, including SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642 injection, and others [1] - The approved clinical trials will be conducted in the near future, indicating a proactive approach in expanding the company's product pipeline [1]

Core Viewpoint - Heng Rui Medicine (01276) experienced a stock price increase of over 5%, reaching HKD 69.3 with a trading volume of HKD 141 million following the announcement of new clinical trial approvals by the National Medical Products Administration [1] Group 1: Company Developments - On November 21, Heng Rui Medicine announced that it, along with its subsidiaries, received approval for clinical trials for multiple injectable drugs including SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642, and others [1] - The approved drugs include monoclonal antibodies and various formulations, indicating a broadening of the company's clinical pipeline [1]

Investment Rating - The report assigns a "Buy" rating for Jiangsu Hengrui Pharmaceuticals with a target price of Rmb123.000, indicating an expected share price return of 95.5% and an expected total return of 95.9% [4]. Core Insights - Jiangsu Hengrui Pharmaceuticals is positioned as a leading global biopharma, ranking No.2 in the size of its originated pipeline and No.3 in pipeline growth, benefiting from China's status as a significant source of global innovation [4][6]. - The report highlights that approximately 30% of global innovative drug trials originate from China, and about one-third of global innovative pipelines are from China-headquartered companies, indicating a robust growth trajectory for the industry [2][3]. - The Chinese pharmaceutical market shows significant potential for growth in innovative drugs, which currently account for only about 14% of total drug sales in hospitals, compared to much higher percentages in developed markets [3]. Summary by Sections Globalization and Innovation - Jiangsu Hengrui has made substantial progress in globalization, with over 20 global trials ongoing and a diversified portfolio across key therapeutic areas [6]. - The company leverages global partnerships and in-house capabilities to maximize innovation impact, with a strong record in out-licensing and strategic partnerships since 2018 [6]. Market Dynamics - The report notes that the demand for affordable innovation from China is expected to thrive due to increasing pricing pressures and the loss of exclusivity for leading multinational corporations [2]. - China's commitment to supporting innovative drugs is underscored by strong government backing for commercial health insurance, which is anticipated to improve coverage for innovative drugs in the future [3]. Financial Valuation - A discounted cash flow (DCF) approach is used to assess the fair value of Jiangsu Hengrui Pharmaceuticals, with a terminal growth rate of 4% and a weighted average cost of capital (WACC) of 8.3% [7].

Core Insights - The Chinese innovative pharmaceutical industry is experiencing significant transformation, marked by substantial licensing deals and a shift towards global leadership in quality over quantity [2][3][6] - The total amount of License-out upfront payments has surpassed that of the primary market for the first time, indicating a shift in funding dynamics within the industry [13][31] - Despite the growth, there are underlying challenges such as a lack of clinical development capabilities and the undervaluation of early-stage pipelines, leading to a phenomenon of "selling seedlings at a discount" [16][20][24] Group 1: Industry Growth and Transactions - In 2025, the total amount of License-out transactions in China is expected to exceed that of the U.S. by 3.2 times, reflecting a rapid acceleration in drug approvals and a surge in innovative drug development [3][6] - The total amount of BD transactions in the Chinese pharmaceutical sector has surpassed $100 billion, with a significant increase in both the number of deals and transaction values [8][11] - Major transactions include a $125 billion collaboration between Hengrui Medicine and GSK, a $114 billion partnership between Innovent Biologics and Takeda, and a $61.5 billion deal between 3SBio and Pfizer, positioning these deals among the largest in global innovative drug licensing [9][10] Group 2: Challenges and Market Dynamics - The industry faces a stark divide, with leading companies achieving profitability while smaller biotech firms struggle with funding and development risks, leading to a survival of the fittest scenario [28][31] - The proportion of License-out transactions for late-stage clinical projects has only slightly increased, indicating ongoing challenges in clinical development capabilities [16][20] - The gap in clinical trial design and execution between Chinese companies and multinational corporations (MNCs) remains significant, impacting the ability of domestic firms to retain control over late-stage assets [19][21][24] Group 3: Financial Performance and Market Reactions - Innovative drug companies in China reported a revenue increase of 22.1% year-on-year in the first three quarters of 2025, with a notable reduction in net losses [28][31] - The market is becoming more discerning, focusing on clinical value and commercialization potential rather than short-term trading excitement, leading to a more cautious approach to BD transactions [32][33] - The capital market's response to BD transactions has been mixed, with significant deals not necessarily translating into sustained stock price increases, highlighting the need for long-term value realization [32][33]

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5]. Core Viewpoints - The innovative pharmaceutical sector is experiencing high prosperity, with a recommendation for companies like Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi Pharmaceutical, Kelun Pharmaceutical, and Enhua Pharmaceutical to maintain an "Overweight" rating. The report also suggests that Biopharma/Biotech companies such as Kelun Biotech, BeiGene, Baillie Gifford, Yimeng Biotech, Jingxin Pharmaceutical, Teva Biotech, WuXi Biologics, and Ailisi should also be rated "Overweight" as their innovative pipelines are gradually being realized and their performance is entering a growth phase. Additionally, it recommends CXO and upstream pharmaceutical companies like Haoyuan Medicine, Baipusais, WuXi AppTec, WuXi AppTec, and Tigermed to maintain an "Overweight" rating. The report highlights leading medical device companies such as United Imaging, Lepu Medical, Spring Medical, and Huatai Medical as having potential for recovery, also maintaining an "Overweight" rating [5][6]. Summary by Sections - **A-Share Market Performance**: In the third week of November 2025, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index falling by 3.9% and the SW Pharmaceutical and Biological Index declining by 6.9%, ranking 23rd among Shenwan's primary industries [7][9]. - **Hong Kong and US Market Performance**: The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare Index and the Hong Kong Biotechnology Index both down by 7.5%, while the US healthcare sector outperformed, with the S&P Healthcare Select Sector Index rising by 1.8% [17]. - **Valuation Metrics**: As of November 21, 2025, the pharmaceutical sector's premium level relative to the entire A-share market is at a normal level, with a current relative premium rate of 71.8% [13][16].